Improving cognitive training for schizophrenia using neuroplasticity enhancers: Lessons from decades of basic and clinical research

被引:16
作者
Guercio, G. D. [1 ,2 ]
Thomas, M. E. [2 ]
Cisneros-Franco, J. M. [2 ]
Voss, P. [2 ]
Panizzutti, R. [1 ]
de Villers-Sidan, E. [2 ]
机构
[1] Univ Fed Rio de Janeiro, Biomed Sci Inst, Rio De Janeiro, RJ, Brazil
[2] McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst, Montreal, PQ, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Neuroplasticity; Cognition; Biomarkers; Personalized medicine; Cognitive remediation therapy; Precision psychiatry; RANDOMIZED CONTROLLED-TRIAL; ACETYLCHOLINE-RECEPTOR AGONIST; POSTTRAUMATIC-STRESS-DISORDER; D-CYCLOSERINE AUGMENTATION; PRIMARY AUDITORY-CORTEX; D-SERINE; MISMATCH NEGATIVITY; WORKING-MEMORY; DOUBLE-BLIND; CORTICAL PLASTICITY;
D O I
10.1016/j.schres.2018.04.028
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Mounting evidence indicates that schizophrenia is a disorder that stems from maladaptive plasticity within neural circuits and produces broad cognitive deficits leading to loss of autonomy. A large number of studies have identified abnormalities spanning many neurotransmitter systems in schizophrenia, and as a result, a variety of drugs have been developed to attempt to treat these abnormalities and enhance cognition. Unfortunately, positive results have been limited so far. This may be in part because the scope of abnormalities in the schizophrenic brain requires a treatment capable of engaging many different neurotransmitter systems. One approach to achieving this kind of treatment has been to use neuroplasticity-based computerized cognitive training programs to stimulate the formation of more adaptive circuits. Although the number of studies implementing this approach has increased exponentially in recent years, effect sizes for cognitive gains have been modest and adherence to treatment remains an important challenge in many studies, as patients are often required to train for 40 h or more. In the present paper, we argue that cognitive training protocols will benefit from the addition of cognitive enhancers to produce more robust and longer lasting targeted neuroplastidty. Indeed, recent data from animal studies have provided support for combining plasticity-enhancing drugs with tailored behavioral training paradigms to restore normal function within dysfunctioning neural circuits. The advantages and challenges of applying this approach to patients with schizophrenia will be discussed. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 92
页数:13
相关论文
共 170 条
  • [1] When Top-Down Meets Bottom-Up: Auditory Training Enhances Verbal Memory in Schizophrenia
    Adcock, R. Alison
    Dale, Corby
    Fisher, Melissa
    Aldebot, Stephanie
    Genevsky, Alexander
    Simpson, Gregory V.
    Nagarajan, Srikantan
    Vinogradov, Sophia
    [J]. SCHIZOPHRENIA BULLETIN, 2009, 35 (06) : 1132 - 1141
  • [2] Amiaz R, 2015, ISR J PSYCHIATR REL, V52, P12
  • [3] Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder
    Arion, D.
    Corradi, J. P.
    Tang, S.
    Datta, D.
    Boothe, F.
    He, A.
    Cacace, A. M.
    Zaczek, R.
    Albright, C. F.
    Tseng, G.
    Lewis, D. A.
    [J]. MOLECULAR PSYCHIATRY, 2015, 20 (11) : 1397 - 1405
  • [4] Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia
    Arnsten, Amy F. T.
    Girgis, Ragy R.
    Gray, David L.
    Mailman, Richard B.
    [J]. BIOLOGICAL PSYCHIATRY, 2017, 81 (01) : 67 - 77
  • [5] Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders
    Arnsten, Amy F. T.
    Wang, Min
    Paspalas, Constantinos D.
    [J]. PHARMACOLOGICAL REVIEWS, 2015, 67 (03) : 681 - 696
  • [6] AXELSSON A, 1989, British Journal of Audiology, V23, P53, DOI 10.3109/03005368909077819
  • [7] Induction of a physiological memory in the cerebral cortex by stimulation of the nucleus basalis
    Bakin, JS
    Weinberger, NM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) : 11219 - 11224
  • [8] Balu DT, 2016, ADV PHARMACOL, V76, P351, DOI 10.1016/bs.apha.2016.01.006
  • [9] Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction
    Balu, Darrick T.
    Li, Yan
    Puhl, Matthew D.
    Benneyworth, Michael A.
    Basu, Alo C.
    Takagi, Shunsuke
    Bolshakov, Vadim Y.
    Coyle, Joseph T.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (26) : E2400 - E2409
  • [10] Cortical remodelling induced by activity of ventral tegmental dopamine neurons
    Bao, SW
    Chan, WT
    Merzenich, MM
    [J]. NATURE, 2001, 412 (6842) : 79 - 83